Skip to main
IMVT

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant Inc's developments in the potential treatment of autoimmune diseases, particularly through its candidate IMVT-1402, highlight promising results with a sustained reduction in TRAb levels during off-treatment periods, indicating potential for disease modification. The impressive responder rate of 81% observed in patients who were previously unresponsive to antithyroid drug therapy offers compelling evidence of durability and efficacy, comparable to active treatment rates. These factors contribute to a positive outlook on Immunovant's stock, suggesting a strong foundation for future growth and patient impact within the immunology sector.

Bears say

Immunovant Inc. operates within a niche segment focused on developing therapies for autoimmune diseases, yet it faces challenges reflected in persistently high levels of TRAbs, which are linked to increased relapse rates. This high incidence of TRAbs suggests underlying issues in effectively managing the conditions targeted by its lead candidate, IMVT-1402, raising concerns about the potential efficacy and market acceptance of the treatment. Furthermore, the complications associated with TRAbs-mediated activation could pose additional risks, potentially limiting the company's ability to advance in the market and impacting overall financial performance.

Immunovant Inc (IMVT) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 8 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Feb 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.